Ernesto Guccione, PhD
img_Ernesto Guccione
PROFESSOR | Oncological Sciences
PROFESSOR | Pharmacological Sciences
Research Topics
Cancer, Developmental Biology, Epigenetics, Post-Transcriptional Processing
Multi-Disciplinary Training Area
Cancer Biology [CAB], Development Regeneration and Stem Cells [DRS]
Post-Transcriptional Processing, Epigenetics, Developmental Biology, Cancer
The Guccione lab has a long-standing interest in understanding basic mechanisms of transcriptional and post-transcriptional regulation in order to identify therapeutic opportunities in oncology. Currently, we are interested in the function in development and disease of Protein MethylTrasnferases (PMTs) and in modulation of Alternative Splicing using Antisense Oligonucleotide (AON)-based approaches. We use biochemistry, mouse models and next generation sequencing techniques to understand the molecular mechanisms of action of candidate PMTs or specific isoforms. The range of techniques and approaches used in the lab has allowed us to characterize the mechanism of action of specific PMTs (e.g. PRMT5 and PRMT6) or oncogenic isoforms (e.g. MDM4l/s), which are now of great interest for their clinical applications.

MS, University of Bologna

PhD, International School for Advanced Studies (SISSA)/International Center for Genetic Engineering Biotechnology (ICGEB)

Post Doc, European Institute of Oncology

Publications

Selected Publications

Anti-correlated feature selection prevents false discovery of subpopulations in scRNAseq. Scott R. Tyler, Daniel Lozano-Ojalvo, Ernesto Guccione, Eric E. Schadt. Nature Communications

Nuclear RNA catabolism controls endogenous retroviruses, gene expression asymmetry, and dedifferentiation. Denis Torre, Yesai S. Fstkchyan, Jessica Sook Yuin Ho, Youngseo Cheon, Roosheel S. Patel, Emma J. Degrace, Slim Mzoughi, Megan Schwarz, Kevin Mohammed, Ji Seon Seo, Raquel Romero-Bueno, Deniz Demircioglu, Dan Hasson, Weijing Tang, Sameehan U. Mahajani, Laura Campisi, Simin Zheng, Won Suk Song, Ying chih Wang, Hardik Shah, Nancy Francoeur, Juan Soto, Zelda Salfati, Matthew T. Weirauch, Peter Warburton, Kristin Beaumont, Melissa L. Smith, Lubbertus Mulder, S. Armando Villalta, Kai Kessenbrock, Cholsoon Jang, Daeyoup Lee, Silvia De Rubeis, Inma Cobos, Oliver Tam, Molly Gale Hammell, Marcus Seldin, Yongsheng Shi, Uttiya Basu, Vittorio Sebastiano, Minji Byun, Robert Sebra, Brad R. Rosenberg, Chris Benner, Ernesto Guccione, Ivan Marazzi. Molecular Cell

G9a/GLP inhibition during ex vivo lymphocyte expansion increases in vivo cytotoxicity of engineered T cells against hepatocellular carcinoma. Maxine S.Y. Lam, Jose Antonio Reales-Calderon, Jin Rong Ow, Joey J.Y. Aw, Damien Tan, Ragavi Vijayakumar, Erica Ceccarello, Tommaso Tabaglio, Yan Ting Lim, Wang Loo Chien, Fritz Lai, Anthony Tan Tanoto, Qingfeng Chen, Radoslaw M. Sobota, Giulia Adriani, Antonio Bertoletti, Ernesto Guccione, Andrea Pavesi. Nature Communications

View All Publications

Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device, biotechnology companies, and other outside entities to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their outside financial relationships.

Below are financial relationships with industry reported by Dr. Guccione during 2023 and/or 2024. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.

Board Service

  • Prometeo Therapeutics

Consulting or Other Professional Services: Examples include, but are not limited to, committee participation, data safety monitoring board (DSMB) membership

  • Hyris
  • Prometeo Therapeutics

Corporate Executive Leadership Roles (CEO, COO, CFO, CSO, CMO, CTO): Examples include board or executive leadership roles in outside entities

  • Prometeo Therapeutics

Editorial Services

  • Epigenomes

Equity (Stock or stock options valued at greater than 5% ownership of a publicly traded company or equity of any value in a privately held company)

  • LION TCR
  • ImmuNOA Pte. Ltd
  • Prometeo Therapeutics

Founder/Co-Founder/Partner:

  • ImmuNOA Pte. Ltd
  • Prometeo Therapeutics

Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.